Synopsis
Treat postmenopausal bleeding as a cancer-exclusion presentation, localise genital and non-genital sources, interpret transvaginal endometrial thresholds in ordinary and HRT contexts, and escalate persistent or recurrent bleeding to histology.
- Postmenopausal bleeding means vaginal bleeding after at least 12 months of spontaneous amenorrhoea from menopause; ask about HRT, tamoxifen, anticoagulants and whether blood may be urinary or rectal.
- Refer unexplained PMB through the urgent suspected-cancer pathway at age 55 or older under NICE and consider the same pathway in younger patients.
- Examine vulva, vagina and cervix with consent and a chaperone to identify atrophy, trauma, polyp or visible malignancy, but continue endometrial assessment even when atrophy seems likely.
Key red flags
Any genital bleeding more than 12 months after the final spontaneous menstrual period is abnormal and should not be dismissed as a late period.
A second episode after an initially reassuring scan can reflect a missed focal lesion and reactivates specialist assessment.
Investigation priorities
Apply NICE age and symptom criteria and avoid delay while routine tests are arranged.
Management branches
Any unexplained genital bleeding occurs after established menopause.
- Apply NICE suspected-cancer referral criteria immediately, document HRT, tamoxifen, anticoagulants, risk and whether urinary or rectal bleeding is possible.
- Perform consented vulval, speculum and pelvic examination and arrange transvaginal ultrasound within the urgent local pathway.